Logo

Cardiff Oncology Reports Results of Onvansertib in P-Ib/II Trial for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer

Share this
Cardiff Oncology Reports Results of Onvansertib in P-Ib/II Trial for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer

Tuba Khan

Cardiff Oncology Reports Results of Onvansertib in P-Ib/II Trial for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer

Shots:

  • The P-Ib/II trial evaluates the safety and preliminary efficacy of onvansertib + Folfiri and Avastin in 2L treatment of patients with KRAS-mutated mCRC
  • As of July 2- 2021- 42% patients achieved a partial response at RP2D (15 mg/m2 dose); confirmed PR (37%); ORR (5-13%); mPFS has not yet reached. Additionally- 38% patients achieved an initial PR who treated at all dose levels (12 mg/m2- 15 mg/m2- 18 mg/m2); confirmed PR (31%); mPFS (9.4mos.) across all response-evaluable patients
  • Additionally- partial responses were observed across different KRAS mutation variants. The combination is well-tolerated and showed the synergistic effect

Click here to read full press release/ article | Ref: Cardiff Oncology | Image: PharmaLive

Click Here

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family